Annual report [Section 13 and 15(d), not S-K Item 405]

Audit Information

v3.25.1
Audit Information
 12 Months Ended
Dec. 31, 2024
Auditor [Table]  
Auditor Name Marcum LLP
Auditor Firm ID 688
Auditor Location New Haven, CT
Auditor Opinion [Text Block]

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Pasithea Therapeutics Corporation (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023 and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024 in conformity with accounting principles generally accepted in the United States of America.